Continuous intracerebroventricular administration of a novel dopamine formulation appears safe in Parkinson's disease and may ...

Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to ...

Tavapadon, an investigational D1/D5 dopamine receptor partial agonist, improved scores on the combined part II and III ...

Annovis is at the forefront, testing buntanetap in pivotal clinical trials as a therapy for Alzheimer's and Parkinson's diseases (PD). Company has filed three new patents protecting combinations of ...

Alzheimer's disease (AD) has become a focal point in the pharmaceutical industry as recent drugs such as Leqembi and Kisunla have received ...

On CNBC's "Halftime Report Final Trades," Kevin Simpson of Capital Wealth Planning said Meta Platforms is hitting on all ...

Leerink Partners analyst David Risinger has maintained their neutral stance on ABBV stock, giving a Hold rating on September 13. David ...

The phase 3 Tempo-1 trial for tavapadon, a dopamine receptor partial agonist, demonstrated significant efficacy as a monotherapy in early Parkinson's disease. Patients receiving the drug at doses of 5 ...

Results from TEMPO-1, which showed that tavapadon significantly improved motor symptoms in patients with Parkinson’s disease, ...

The Phase III TEMPO-1 trial enrolled 529 adults aged between 40 and 80 years, diagnosed with Parkinson’s for less than three ...

The Phase III TEMPO-1 trial enrolled 529 adults, between the ages of 40 and 80, diagnosed with Parkinson’s for less than three years.

Tavapadon, a drug made by AbbVie to treat Parkinson’s disease, met phase 3 TEMPO-1 trial goals treated early Parkinson's ...